I would say 2 years is well within reach if data is good. Never had an instance where a graft was rejected. I'd say chances are good. ESS is one of those products that could get really fast tracked if the data was really good.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links